Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Aktis OncologyAKTS | Open-market sale10b5-1 plan | 09/23 | 09/24 | 12,500 sh2 trades | $20.69avg. | $258,620.99 | −100.0% | |
Ansbert Gadicke10% Owner | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% |
Luke Evnin10% Owner | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% |
MPM Asset Management10% Owner | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% |
Todd FoleyDirector | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 232,870 sh | $18.00 | $4,191,660 | +5.8% |
MPM Oncology Innovations Fund10% Owner | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% |
MPM Bioventures 201810% Owner | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% |
MPM Bioventures 201810% Owner | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% |
Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% | |
MPM BioVentures 2018 GP10% Owner | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% |
MPM BioVentures 201810% Owner | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% |
MPM Oncology Innovations Fund GP10% Owner | Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% |
Aktis OncologyAKTS | Open-market buy | 01/12 | 01/14 | 1,112,777 sh | $18.00 | $20,029,986 | +12.2% | |
Aktis OncologyAKTS | Open-market buy | 01/12 | 01/12 | 835,000 sh2 trades | $18.00avg. | $15,030,000 | No record | |
Aktis OncologyAKTS | Open-market buy | 01/12 | 01/12 | 2,222,222 sh2 trades | $18.00avg. | $39,999,996 | No record | |
Aktis OncologyAKTS | Open-market buy | 01/12 | 01/12 | 2,222,222 sh2 trades | $18.00avg. | $39,999,996 | No record | |
Aktis OncologyAKTS | Open-market buy | 01/12 | 01/12 | 835,000 sh2 trades | $18.00avg. | $15,030,000 | No record | |
Aktis OncologyAKTS | Open-market buy | 01/12 | 01/12 | 835,000 sh2 trades | $18.00avg. | $15,030,000 | No record | |
Arthur GeissDirector | Akoustis Technologies | Open-market buy | 24/01/29 | 24/01/31 | 50,000 sh | $0.50 | $25,000 | +13.7% |
David AicheleEVP of Business Development | Akoustis Technologies | Open-market buy | 24/01/29 | 24/01/31 | 80,000 sh | $0.50 | $40,000 | +31.4% |